PT2389166E - Composição farmacêutica contendo aleglitazar - Google Patents

Composição farmacêutica contendo aleglitazar

Info

Publication number: PT2389166E
Authority: PT; Portugal
Prior art keywords: aleglitazar; pharmaceutical composition; pharmaceutical; composition
Prior art date: 2009-01-23

Application number

PT107013401T

Other languages

English (en)

Inventor

Alexander Glomme

Paul Wojtera

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-23

Filing date

2010-01-13

Publication date

2013-01-08

2010-01-13 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2013-01-08 Publication of PT2389166E publication Critical patent/PT2389166E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Biophysics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

PT107013401T 2009-01-23 2010-01-13 Composição farmacêutica contendo aleglitazar PT2389166E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP09151254		2009-01-23

Publications (1)

Publication Number	Publication Date
PT2389166E true PT2389166E (pt)	2013-01-08

Family

ID=42112184

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT107013401T PT2389166E (pt)	2009-01-23	2010-01-13	Composição farmacêutica contendo aleglitazar

Country Status (25)

Country	Link
US (2)	US20100190835A1 (pt)
EP (1)	EP2389166B1 (pt)
JP (1)	JP5619027B2 (pt)
KR (2)	KR20110105798A (pt)
CN (1)	CN102292074B (pt)
AR (1)	AR075041A1 (pt)
AU (1)	AU2010206249B2 (pt)
BR (1)	BRPI1007237B1 (pt)
CA (1)	CA2748896C (pt)
CL (1)	CL2011001777A1 (pt)
CY (1)	CY1113641T1 (pt)
DK (1)	DK2389166T3 (pt)
ES (1)	ES2397558T3 (pt)
HR (1)	HRP20130108T1 (pt)
IL (1)	IL213671A (pt)
MX (1)	MX2011007381A (pt)
PE (2)	PE20160746A1 (pt)
PL (1)	PL2389166T3 (pt)
PT (1)	PT2389166E (pt)
RU (1)	RU2537224C2 (pt)
SG (1)	SG173058A1 (pt)
SI (1)	SI2389166T1 (pt)
TW (1)	TWI406861B (pt)
WO (1)	WO2010084066A1 (pt)
ZA (1)	ZA201104670B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013181384A1 (en)	2012-05-31	2013-12-05	Ratiopharm Gmbh	Solid state forms of aleglitazar sodium
WO2014016371A1 (en)	2012-07-27	2014-01-30	Ratiopharm Gmbh	Micronized aleglitazar
WO2014016370A1 (en) *	2012-07-27	2014-01-30	Ratiopharm Gmbh	Amorphous aleglitazar
WO2014016369A1 (en)	2012-07-27	2014-01-30	Ratiopharm Gmbh	Pharmaceutical formulation comprising aleglitazar and complexing agent
WO2014040936A1 (en) *	2012-09-12	2014-03-20	F. Hoffmann-La Roche Ag	Solid forms of (s)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid and of salts thereof
KR102766096B1 (ko) *	2016-08-10	2025-02-12	에프. 호프만-라 로슈 아게	Akt 단백질 키나아제 저해제를 포함하는 약학 조성물
CN114404375B (zh) *	2022-01-21	2023-06-27	武汉九珑人福药业有限责任公司	一种叶酸固体制剂及其原料组合物、制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2772615B1 (fr) *	1997-12-23	2002-06-14	Lipha	Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
ES2264482T3 (es) *	2001-05-15	2007-01-01	F. Hoffmann-La Roche Ag	Derivados de oxazol sustituidos por acido carboxilico para uso como activadores de ppar-alfa y gamma en el tratamiento de diabetes.
GB0303600D0 (en) *	2003-02-17	2003-03-19	Glaxo Group Ltd	Novel therapeutic method and compositions
US7262303B2 (en) *	2003-09-29	2007-08-28	Hoffman-La Roche Inc.	Process for the production of chiral propionic acid derivatives
US20060051413A1 (en) *	2004-09-08	2006-03-09	Chow Sing S M	Method of enhancing absorptions of transmucosal administration formulations
WO2006089674A2 (en) *	2005-02-25	2006-08-31	F.Hoffmann-La Roche Ag	Tablets with improved drug substance dispersibility
US20060270722A1 (en) *	2005-05-31	2006-11-30	Thornberry Nancy A	Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
FR2894477A1 (fr) *	2005-12-13	2007-06-15	Galderma Res & Dev	Utilisation du naveglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
WO2008119070A1 (en) *	2007-03-28	2008-10-02	Trustees Of Boston University	Methods of treatment using sirt modulators and compositions containing sirt1 modulators

2010
- 2010-01-13 AU AU2010206249A patent/AU2010206249B2/en not_active Ceased
- 2010-01-13 CA CA2748896A patent/CA2748896C/en not_active Expired - Fee Related
- 2010-01-13 WO PCT/EP2010/050343 patent/WO2010084066A1/en not_active Ceased
- 2010-01-13 SI SI201030129T patent/SI2389166T1/sl unknown
- 2010-01-13 EP EP10701340A patent/EP2389166B1/en not_active Not-in-force
- 2010-01-13 KR KR1020117016128A patent/KR20110105798A/ko not_active Ceased
- 2010-01-13 BR BRPI1007237-3A patent/BRPI1007237B1/pt not_active IP Right Cessation
- 2010-01-13 JP JP2011546748A patent/JP5619027B2/ja not_active Expired - Fee Related
- 2010-01-13 PL PL10701340T patent/PL2389166T3/pl unknown
- 2010-01-13 CN CN2010800050015A patent/CN102292074B/zh not_active Expired - Fee Related
- 2010-01-13 PT PT107013401T patent/PT2389166E/pt unknown
- 2010-01-13 DK DK10701340.1T patent/DK2389166T3/da active
- 2010-01-13 RU RU2011134964/15A patent/RU2537224C2/ru not_active IP Right Cessation
- 2010-01-13 KR KR1020137032602A patent/KR20140002812A/ko not_active Ceased
- 2010-01-13 SG SG2011052305A patent/SG173058A1/en unknown
- 2010-01-13 ES ES10701340T patent/ES2397558T3/es active Active
- 2010-01-13 MX MX2011007381A patent/MX2011007381A/es active IP Right Grant
- 2010-01-13 PE PE2016000386A patent/PE20160746A1/es unknown
- 2010-01-13 PE PE2011001309A patent/PE20120421A1/es not_active Application Discontinuation
- 2010-01-13 HR HRP20130108AT patent/HRP20130108T1/hr unknown
- 2010-01-19 US US12/689,296 patent/US20100190835A1/en not_active Abandoned
- 2010-01-21 AR ARP100100131A patent/AR075041A1/es not_active Application Discontinuation
- 2010-01-22 TW TW099101817A patent/TWI406861B/zh not_active IP Right Cessation
2011
- 2011-06-20 IL IL213671A patent/IL213671A/en unknown
- 2011-06-23 ZA ZA2011/04670A patent/ZA201104670B/en unknown
- 2011-07-22 CL CL2011001777A patent/CL2011001777A1/es unknown
2012
- 2012-11-12 US US13/674,310 patent/US20130072529A1/en not_active Abandoned
- 2012-12-03 CY CY20121101181T patent/CY1113641T1/el unknown

Also Published As

Publication number	Publication date
BRPI1007237A2 (pt)	2016-02-16
ES2397558T3 (es)	2013-03-07
KR20140002812A (ko)	2014-01-08
EP2389166B1 (en)	2012-11-21
MX2011007381A (es)	2011-08-12
PE20160746A1 (es)	2016-08-01
RU2537224C2 (ru)	2014-12-27
RU2011134964A (ru)	2013-02-27
EP2389166A1 (en)	2011-11-30
CL2011001777A1 (es)	2012-02-24
ZA201104670B (en)	2012-03-28
BRPI1007237B1 (pt)	2019-05-28
PL2389166T3 (pl)	2013-04-30
IL213671A0 (en)	2011-07-31
CY1113641T1 (el)	2016-06-22
PE20120421A1 (es)	2012-05-04
CA2748896A1 (en)	2010-07-29
AU2010206249A1 (en)	2011-06-30
WO2010084066A1 (en)	2010-07-29
CA2748896C (en)	2017-01-03
US20130072529A1 (en)	2013-03-21
SI2389166T1 (sl)	2013-02-28
JP2012515741A (ja)	2012-07-12
KR20110105798A (ko)	2011-09-27
TW201035089A (en)	2010-10-01
CN102292074B (zh)	2013-08-21
HRP20130108T1 (hr)	2013-03-31
US20100190835A1 (en)	2010-07-29
AU2010206249B2 (en)	2015-07-09
JP5619027B2 (ja)	2014-11-05
TWI406861B (zh)	2013-09-01
SG173058A1 (en)	2011-08-29
AR075041A1 (es)	2011-03-02
CN102292074A (zh)	2011-12-21
IL213671A (en)	2015-11-30
DK2389166T3 (da)	2012-12-17

Publication	Publication Date	Title
ZA201107776B (en)	2014-03-26	Pharmaceutical composition
IL228817A0 (en)	2013-12-31	Pharmaceutical compounds
SG2014012405A (en)	2014-05-29	Pharmaceutical compositions
EP2379077A4 (en)	2013-09-11	PHARMACEUTICAL COMPOSITION
SI2442799T2 (sl)	2019-08-30	Trden farmacevtski sestavek, ki obsega rivaroksaban
IL220097A (en)	2017-03-30	Pharmaceutical preparation containing oligopeptides
IL208387A0 (en)	2010-12-30	Pharmaceutical composition
ZA201104670B (en)	2012-03-28	Pharmaceutical composition comprising aleglitazar
ZA201006224B (en)	2011-11-30	Pharmaceutical composition
GB2464200B (en)	2013-05-08	Pharmaceutical composition
IL219018A0 (en)	2012-06-28	Pharmaceutical compositions
GB0817969D0 (en)	2008-11-05	Pharmaceutical composition
GB0919650D0 (en)	2009-12-23	Pharmaceutical composition
HU0900010D0 (en)	2009-03-30	Improved pharmaceutical composition
HU0800741D0 (en)	2009-03-02	Improved pharmaceutical composition
GB0817974D0 (en)	2008-11-05	Pharmaceutical composition
GB0817566D0 (en)	2008-11-05	Pharmaceutical composition
GB0910225D0 (en)	2009-07-29	Pharmaceutical compositions